Chevy Chase Trust’s Myriad Genetics MYGN Stock Holding History

Chevy Chase Trust’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-555	Closed	-$15K	–	875
2019 Q4	$15K	Buy	+555	New	+$15.3K	﹤0.01%	1029

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Chevy Chase Trust's MYGN Position: Q1 2020 in Review

Chevy Chase Trust sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 555 shares — an estimated $15K sold.

Chevy Chase Trust first reported a position in MYGN in Q4 2019 and held it in 1 quarter. The position peaked at $15K in Q4 2019. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

Chevy Chase Trust reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
Chevy Chase Trust sold 555 Myriad Genetics shares in Q1 2020, an estimated $15K.
Chevy Chase Trust first reported a position in Myriad Genetics in Q4 2019 and held it in 1 quarter.
Chevy Chase Trust's Myriad Genetics position peaked at $15K in Q4 2019.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Chevy Chase Trust's 13F filing for Q1 2020, filed 13 May 2020.